J Korean Med Sci.  2009 Jun;24(3):438-442. 10.3346/jkms.2009.24.3.438.

Association of Interleukin-10 A-592C Polymorphism in Taiwanese Children with Kawasaki Disease

• Hsueh KC
• Lin YJ
• Chang JS
• Wan L
• Tsai YH
• Tsai CH
• Chen CP
• Tsai FJ

• KMID: 1779160
• DOI: http://doi.org/10.3346/jkms.2009.24.3.438

Abstract

Elevated serum levels of interleukin-10 (IL-10) have been reported in patients with Kawasaki disease (KD). IL-10 reduces the inflammatory actions of macrophages and T cells and it may play a significant role in the regulation of inflammatory vascular damage associated with systemic vasculitis. The aim of this study was to examine whether -592 IL-10 promoter polymorphism is a susceptibility or severity marker of KD in Chinese patients in Taiwan. The study included 105 KD patients and 100 normal controls. Genotype and allelic frequencies for the IL-10 gene polymorphism in both groups were compared. There were no significant between-group differences in the genotype distribution of IL-10 A-592C gene polymorphism (P=0.08). However, the frequency of the -592*A allele was significantly increased in the patients with KD compared with controls (71.9% vs. 61.0%, P=0.019). The odds ratio for developing KD in individuals with IL-10-592*A allele was 1.64 (95% confidence interval, 1.06-2.52) compared to individuals with the IL-10-592*C allele. No significant difference was observed in the genotype and allelic frequencies for the IL-10 A-592C polymorphism between patients with and without coronary artery lesions. The IL-10-592*A allele may be involved in the development of KD in Taiwanese children.

Keyword

Mucocutaneous Lymph Node Syndrome; Polymorphism; Interleukin-10

MeSH Terms

Alleles
Asian Continental Ancestry Group/*genetics
Child
Child, Preschool
Female
Gene Frequency
Genotype
Humans
Infant
Interleukin-10/blood/*genetics
Male
Mucocutaneous Lymph Node Syndrome/diagnosis/*genetics
Polymorphism, Genetic
Promoter Regions, Genetic
Taiwan

Reference

1. Wang CL, Wu YT, Liu CA, Kuo HC, Yang KD. Kawasaki disease: infection, immunity and genetics. Pediatr Infect Dis J. 2005. 24:998–1004.

2. Lin CY, Lin CC, Hwang B, Chiang BN. The changes of interleukin-2, tumor necrosis factor, and gamma-interferon production among patients with Kawasaki disease. Eur J Pediatr. 1991. 150:179–182.

3. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr. 1992. 121:924–926.

4. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990. 56:29–36.

5. Hirao J, Hibi S, Andoh T, Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int Arch Allergy Immunol. 1997. 112:152–156.

6. Eberhard BA, Andersson U, Laxer RM, Rose V, Silverman ED. Evaluation of the cytokine response in Kawasaki disease. Pediatr Infect Dis J. 1995. 14:199–203.

7. Kim DS, Lee HK, Noh GW, Lee SI, Lee KY. Increased serum interleukin-10 level in Kawasaki disease. Yonsei Med J. 1996. 37:125–130.

8. Noh GW, Lee WG, Lee W, Lee K. Effects of intravenous immunoglobulin on plasma interleukin-10 levels in Kawasaki disease. Immunol Lett. 1998. 62:19–24.

9. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol. 1994. 56:1–2.

10. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J Exp Med. 1989. 170:2081–2095.

11. Taga K, Tosato G. IL-10 inhibits T cell proliferation and IL-2 production. J Immunol. 1992. 148:1143–1148.

12. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol. 1993. 151:1224–1234.

13. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991. 174:1209–1220.

14. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J. Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA. 1992. 89:1890–1893.

15. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001. 19:683–765.

16. Kim JM, Brannan CI, Copeland NG, Jenkins NA, Khan TA, Moore KW. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol. 1992. 148:3618–3623.

17. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997. 349:170–173.

18. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA. 1998. 95:9465–9470.

19. Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. 1984. Tokyo: Ministry of Health and Welfare of Japan.

20. Furukawa F, Ohshio G, Hamashima Y. Possible polyclonal B cell activation in mucocutaneous lymph node syndrome. Eur J Pediatr. 1986. 145:104–108.

21. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5'flanking sequence. Immunogenetics. 1997. 46:120–128.

22. Rosenwasser LJ, Borish L. Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am J Respir Crit Care Med. 1997. 156:S152–S155.

23. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997. 24:1–8.

24. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999. 30:526–530.

25. Kube D, Platzer C, von Knethen A, Straub H, Bohlen H, Hafner M, Tesch H. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine. 1995. 7:1–7.

26. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med. 2003. 31:34–38.

27. Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 1998. 41:1090–1095.

28. Tegoshi H, Hasegawa G, Obayashi H, Nakano K, Kitagawa Y, Fukui M, Matsuo S, Deguchi M, Ohta M, Nishimura M, Nakamura N, Yoshidawa T. Polymorphisms of interferon-γ gene CA-repeat and interleukin-10 promoter region (-592A/C) in Japanese type 1 diabetes. Hum Immunol. 2002. 63:121–128.

29. Chin HJ, Na KY, Kim SJ, Oh KH, Kim YS, Lim CS, Kim S, Chae DW. Interleukin-10 promoter polymorphism is associated with the predisposition to the development of IgA nephropathy and focal segmental glomerulosclerosis in Korea. J Korean Med Sci. 2005. 20:989–993.

30. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004. 110:2747–2771.

31. Jin HS, Kim HB, Kim BS, Lee JK, Seo EJ, Yoo HW, Park IS, Hong YM, Hong SJ. The IL-10 (-627 A/C) promoter polymorphism may be associated with coronary aneurysms and low serum albumin in Korean children with Kawasaki disease. Pediatr Res. 2007. 61:584–587.